SG11201502430QA - Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates - Google Patents

Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Info

Publication number
SG11201502430QA
SG11201502430QA SG11201502430QA SG11201502430QA SG11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA
Authority
SG
Singapore
Prior art keywords
cell
ion exchange
exchange membrane
remove impurities
binding agent
Prior art date
Application number
SG11201502430QA
Inventor
Xinfang Li
Wenjie Cheng
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11201502430QA publication Critical patent/SG11201502430QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
SG11201502430QA 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates SG11201502430QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
SG11201502430QA true SG11201502430QA (en) 2015-04-29

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502430QA SG11201502430QA (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Country Status (13)

Country Link
US (1) US20150307596A1 (en)
EP (1) EP2903450A4 (en)
JP (1) JP2015535215A (en)
CN (1) CN105208876A (en)
AU (1) AU2013326897A1 (en)
CA (1) CA2886996A1 (en)
HK (1) HK1213148A1 (en)
IL (1) IL238111A0 (en)
IN (1) IN2015DN03203A (en)
MX (1) MX2015004258A (en)
RU (1) RU2015116883A (en)
SG (1) SG11201502430QA (en)
WO (1) WO2014055893A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609752A (en) 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
PT2437790T (en) 2009-06-03 2019-06-04 Immunogen Inc Conjugation methods
RS58367B1 (en) 2011-03-29 2019-03-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
IN2015DN03202A (en) * 2012-10-04 2015-10-02 Immunogen Inc
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (en) * 2018-04-09 2021-06-01 电子科技大学 Charge exchange collision MCC method for numerical simulation of ion thruster
CN118290513A (en) * 2024-06-05 2024-07-05 东曜药业有限公司 Anion column chromatography method for removing free small molecules in antibody-coupled drug and antibody-coupled drug
CN118290514A (en) * 2024-06-05 2024-07-05 东曜药业有限公司 Method for purifying antibody-coupled drug based on anion membrane and antibody-coupled drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201824A1 (en) * 2002-01-03 2003-07-24 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP5165387B2 (en) * 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド Method for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
NZ609752A (en) * 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
PT2437790T (en) * 2009-06-03 2019-06-04 Immunogen Inc Conjugation methods
RS58367B1 (en) * 2011-03-29 2019-03-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process

Also Published As

Publication number Publication date
MX2015004258A (en) 2015-09-25
IN2015DN03203A (en) 2015-10-02
CN105208876A (en) 2015-12-30
US20150307596A1 (en) 2015-10-29
HK1213148A1 (en) 2016-06-30
EP2903450A4 (en) 2016-05-11
EP2903450A1 (en) 2015-08-12
RU2015116883A (en) 2016-11-27
IL238111A0 (en) 2015-05-31
AU2013326897A1 (en) 2015-05-07
WO2014055893A1 (en) 2014-04-10
JP2015535215A (en) 2015-12-10
CA2886996A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
IL277652A (en) Stable aqueous formulations of adalimumab
IL268378A (en) Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
IL238111A0 (en) Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates
ZA201605918B (en) Preparation of cell-binding agent cytotoxic agent conjugates
HK1212701A1 (en) Formulations of enzalutamide
HK1213174A1 (en) Stable aqueous formulations of etanercept
SG10201609982PA (en) Pharmaceutical formulations of tnf-alpha anitbodies
ZA201500212B (en) Progesterone formulations
SI3336097T1 (en) Preparation of the non-crystalline form of obeticholic acid
PL2627334T3 (en) Compositions for use in the treatment of viral infections
SG11201405605VA (en) SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
PT2908835T (en) Stable formulations
EP2867199A4 (en) Stable compositions of fesoterodine
EP2754451A4 (en) The use of ache as nuclease
IL233879A0 (en) Drypowder formulations of dnase i